Diabetic Lancets Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Haemoglobin Testing is the fastest growing sector, North America is the largest market

The global market for diabetic lancets, which are sterile, disposable devices used to obtain capillary blood for glucose analysis, is projected to expand from USD 2.54 billion in 2025 to USD 4.38 billion by 2031, demonstrating a compound annual growth rate of 9.51%. This growth is predominantly fueled by the increasing worldwide prevalence of diabetes and the essential requirement for consistent blood glucose monitoring to avert health complications. For instance, the International Diabetes Federation reported that around 589 million adults globally were living with diabetes in 2025. This expanding patient demographic, coupled with broader healthcare coverage for diabetes management products in developing economies, significantly underpins the demand for these crucial consumables.

However, the market's expansion faces a notable challenge due to the accelerating adoption of continuous glucose monitoring (CGM) systems. These advanced systems reduce the necessity for frequent invasive finger-prick testing by enabling patients to track their glucose levels without repeated skin punctures. This technological shift poses a considerable constraint on the future volume growth of the conventional lancet market.

Market Drivers

The primary catalyst for the diabetic lancets market is the escalating global prevalence of diabetes mellitus, which fundamentally enlarges the patient base needing daily glucose management. Urbanization and evolving lifestyles are fueling a metabolic health crisis, leading to an unprecedented surge in patients requiring frequent blood glucose testing, thereby increasing the demand for disposable lancing devices. Recent epidemiological data corroborates this trend, indicating a significantly higher disease burden than previously estimated.

As reported by the World Health Organization in November 2024, the number of adults with diabetes worldwide has quadrupled since 1990, now exceeding 800 million. This substantial patient population directly drives the sustained, high-volume consumption of lancets, particularly in regions where continuous monitoring technologies are not yet economically viable. The vast commercial scale of the diabetes injection and testing supplies sector is evident, for instance, in Embecta Corp.'s December 2024 report of $1.13 billion in annual revenues.

Concurrently, heightened awareness concerning early detection and glucose monitoring is revealing a considerable untapped market segment, boosting demand for lancets in screening and preventative care. Public health and educational efforts are increasingly concentrating on identifying asymptomatic individuals to prevent severe long-term complications, a strategy heavily dependent on capillary blood sampling with lancets for initial diagnosis and routine spot-checking. The scale of this undiagnosed market is significant; the International Diabetes Federation's April 2025 update noted that around 252 million adults living with diabetes remain undiagnosed. As healthcare systems proactively target this population to reduce future medical expenses, the use of both safety and standard lancets in screening programs is anticipated to increase sharply, further bolstering market growth despite the competition from advanced monitoring technologies.

Market Challenges

The global diabetic lancets market faces a considerable hurdle primarily due to the extensive technological shift towards Continuous Glucose Monitoring (CGM) systems. In contrast to conventional testing, which demands repeated skin punctures for each glucose measurement, CGM devices employ subcutaneous sensors to deliver real-time data over prolonged durations. This significantly curtails the need for frequent finger-stick tests. This technological evolution fundamentally disrupts the high-volume, recurring revenue model typical of the lancet industry, as patients increasingly favor semi-automated monitoring solutions over manual testing.

The implications of this transition are becoming more pronounced as CGM adoption broadens from Type 1 diabetes to include the much larger Type 2 patient population, which, according to the International Diabetes Federation in 2025, accounted for over 90% of all individuals with diabetes. As healthcare standards increasingly recommend sensor-based monitoring for this vast group to enhance glycemic management, the commercial demand for disposable lancets is set for a clear decline. Subsequently, the role of lancets is transitioning from a daily essential to a supplemental tool, primarily used for infrequent calibration or as a backup testing method.

Market Trends

A prominent trend in the diabetic lancets market is the extensive adoption of automatic retractable safety mechanisms, driven by healthcare systems' strong emphasis on protecting staff from bloodborne pathogens. This involves replacing traditional lancets with exposed needles with safety-engineered versions that automatically retract and shield the sharp tip post-use, thereby eliminating the risk of accidental needle-stick injuries. The critical nature of this shift is highlighted by occupational safety statistics; for example, MedPro Disposal reported in December 2025 that needle-stick injuries account for over 80% of all percutaneous exposure incidents in the United States. Consequently, healthcare facilities are increasingly implementing these single-use, auto-disabling devices to ensure regulatory compliance and reduce the significant financial and health liabilities linked to staff injuries.

Concurrently, the industry is witnessing a crucial transition towards eco-friendly and biodegradable materials, a direct response to the considerable environmental impact of disposable diabetes supplies. Manufacturers are increasingly substituting conventional medical-grade plastics with sustainable alternatives, such as plant-based polymers and designs that minimize packaging, to tackle the growing problem of medical waste. This move is supported by clear data on the ecological burden of diabetes management; according to Healio in April 2025, an average individual with diabetes generates between 2.7 lb and 3.3 lb of disease-related waste monthly. This substantial volume of waste compels industry participants to embed sustainability throughout their product lifecycles, aligning with changing consumer demands and environmental regulations.

Key Market Players

• B. Braun SE
• Terumo Medical Corporation
• Medline Industries, LP
• F. Hoffmann-La Roche Ltd.
• ARKRAY, Inc.
• Astellas Pharma Inc.
• Becton, Dickinson and Company
• Nipro Corporation
• Medical Technology and Devices S.p.A.
• Allison Medical, Inc.

Report Scope

In this report, the Global Diabetic Lancets Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Diabetic Lancets Market, by Product Type:

• Standard Lancets
• Safety Lancets
• Manually Activated
• Automatically Activated/Pressure Activated

Diabetic Lancets Market, by Gauge Size:

• 22G and Below
• 23G-33G
• Above 33G

Diabetic Lancets Market, by Application:

• Glucose Testing
• Haemoglobin Testing
• Cholesterol Testing
• Coagulation Testing
• Allergy Testing
• Neonatal Testing
• Others

Diabetic Lancets Market, by End User:

• Hospitals & Clinics
• Diagnostic Centers
• Home Care Settings
• Others

Diabetic Lancets Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diabetic Lancets Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.